Navigation Links
Docetaxel May Boost Outcomes For Breast Cancers That Haven't Spread to Lymph

By Kathleen Doheny
HealthDay Reporter

WEDNESDAY, Dec. 1 (HealthDay News) -- A chemotherapy regimen already proven superior to other regimens for breast cancer that has spread to the lymph nodes may also work better for some women whose cancers haven't spread, a new study has found.

When it came to these "node-negative" cancers, the drug combination of docetaxel, doxorubicin and cyclophosphamide (dubbed TAC) outperformed the combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC), the Spanish study authors said.

The TAC regimen was better at keeping women alive and disease-free after a median follow up of almost six and a half years, the study found.

''For those women with higher-risk, node-negative breast cancer, in which chemotherapy is indicated, TAC is one of the most interesting options," said study co-author Dr. Miguel Martin, a professor of medical oncology at the Hospital General Universitario Gregorio Maranon in Madrid.

The study was funded by the drug maker Sanofi-Aventis -- which makes Taxotere, the brand name for docetaxel -- and GEICAM, the Spanish Breast Cancer Research Group. The results are published in the Dec. 2 issue of the New England Journal of Medicine.

To determine which women with breast cancer would benefit from adjuvant chemotherapy (typically chemotherapy after surgery), doctors take into account a number of risk factors, such as the patient's age, tumor size and other characteristics.

For the new study, the researchers assigned 1,060 women with breast cancers that were axillary-node negative who had at least one high-risk factor for recurrence to one of the two treatment regimens every three weeks for six cycles after their surgery.

At the 77-month mark, almost 88 percent of the TAC women were alive and disease-free, compared to close to 82 percent of the women in the FAC group. Those in the TAC group had a 32 percent reduction in the risk of recurrence, the study authors said.

The reduced risk held true even after taking into account a number of high-risk factors, such as age, the women's menopausal status and tumor characteristics.

The differences in survival rates weren't significant from a statistical point of view -- 95.2 percent of TAC-treated women survived the follow-up, compared to 93.5 percent of the FAC-treated women.

However, adverse events from the drugs were more common with TAC -- 28 percent of patients, compared to 17 percent of the FAC patients.

''TAC is more toxic," Martin said, adding that ''all the toxicities were reversible." One common side effect was neutropenia, an abnormally low number of white blood cells. Fatigue was also a problem, the study found.

Another consideration: TAC chemotherapy is also substantially more expensive than FAC, Martin said, although he could not specify exactly how much more.

Even so, he said, "I think this study provides grounds for thinking of this regimen, particularly for those women with high-risk node-negative breast cancers."

Dr. Minetta Liu, director of translational breast cancer research at the Lombardi Comprehensive Cancer Center at Georgetown University, said the new study supports what many oncologists are already doing.

"Many oncologists are incorporating taxenes [such as docetaxel] in the adjuvant treatment for node-negative breast cancer," said Liu, who reviewed the study findings but was not involved with the research.

The ongoing challenge, Liu said, is deciding which women need the additional therapy. "This particular study's importance is that it illustrates there is a benefit in incorporating a taxene into the adjuvant treatment for some women with node-negative breast cancer."

More information

To learn more about breast cancer treatment, visit the U.S. National Cancer Institute.

SOURCES: Miguel Martin, M.D., Ph.D., professor of medical oncology, Hospital General Universitario Gregorio Maranon, Madrid, Spain; Minetta Liu, M.D., director of translational research, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C.; New England Journal of Medicine, Dec. 2, 2010

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
2. New lung disease network to benefit patients and boost UK economy
3. Love Hormone May Boost Mens Memories of Mom -- Good or Bad
4. Love Hormone Boosts Memories of Mom -- Good or Bad, Study Finds
5. Behavior Disorders Boost Crash Risk for Teen Boys: Study
6. Poor Children Get Biggest Literacy Boost From Preschool
7. Higher Plavix Dose Wont Boost Outcomes After Stent Placement: Study
8. Scientists Find Way to Boost Good Cholesterol in Mice
9. Setting National Hospital Standards Could Boost Cardiac Care
10. Small assist device used in emergency case as twin, heart booster pumps for first time in US
11. Math Skills Boost Couples Financial Worth: Study
Post Your Comments:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/7/2017)... 2017   Provista, a proven leader in ... in purchasing power, today announced a new resource area ... Newsroom is the online home for case studies, ... bios, news releases, slideshows and events. ... of resources at their fingertips, viewers can also watch ...
Breaking Medicine Technology: